ADVFN - Advanced Financial Network.
HOME» NYSE » A » AGN Stock Price » AGN Stock News

Allergan Share News

 Allergan, Stock Price
AGN Stock Price
 Allergan, Stock Chart
AGN Stock Chart
 Allergan, Stock News
AGN Stock News
 Allergan, Company Information
AGN Company Information
 Allergan, Stock Trades
AGN Stock Trades

Inspire Pharma: Dry-Eye Treatment Didn't Meet Study Endpoints

DOW JONES NEWSWIRES Inspire Pharmaceuticals Inc. (ISPH) said its Prolacria treatment for dry eye met neither the primary nor secondary endpoints in a late-stage trial. Shares fell 7.5% to $6.11 premarket. Shares in its partner in developing the eye drops, Allergan Inc. (AGN), weren't active after closing Wednesday at $61.20. Early data about Prolacria had been discouraging, so the final results won't come as a huge surprise, but the treatment had been one of Inspire's most advanced drugs in its pipeline. Its other advanced drug candidate is denufosol tetrasodium for cystic fibrosis. Inspire focuses on developing treatments for ophthalmic and pulmonary diseases. Chief Executive Christy Shaffer said Inspire has reported the results to Allergan and "will be conducting a thorough review of the program before determining next steps, if any." At the end of the six-week study, Inspire gauged subjects extent of dry eye with a "staining score," in which patterns made by a stain are used to measure damaged cells in the central area of the cornea. It aimed to have a proportion of its subjects receiving Prolacria have a staining score of zero compared to a placebo group, its primary endpoint. It also failed to reduce the staining score by two units compared to the control group, the secondary endpoint. Dry eye occurs when the eye isn't being sufficiently lubricated. In November, the drug company reported a narrower third-quarter loss thanks to double-digit growth in sales. -By Joan E. Solsman, Dow Jones Newswires; 212-416-2291; joan.solsman@dowjones.com

Stock News for Allergan (AGN)
DateTimeHeadline
12/16/201409:58:40U.S. Hot Stocks: Hot Stocks to Watch
12/16/201408:48:40Actavis CEO to Remain After Allergan Merger
12/15/201419:53:21Brent Saunders faces challenge of running combined Actavis-Allergan
12/05/201411:45:17Activist Fund ValueAct Capital to Seek Up to $1.5 Billion From...
11/25/201418:53:14CEOs' Test: Contending With Activist Investors
11/24/201417:46:23Salix Plans to Boost Size of Board
11/21/201408:53:08U.S. Stock Futures Rally on China, Draghi
11/20/201412:41:11Valeant Sets $2 Billion Buyback Plan After Losing Allergan
11/19/201419:15:16For Allergan Suitors, Unorthodox Alliance Proved Unwieldy
11/18/201419:55:17Goldman Hits Mother Lode on Deals
11/18/201418:50:13Ackman Drops Push for Allergan Holder Meeting--2nd Update
11/18/201418:40:32Ackman Drops Push for Allergan Holder Meeting--Update
11/18/201409:33:44Actavis Outlines Allergan Breakup Fee, Board Appointments
11/17/201420:01:10Deal Boom Feeds on Surging Stocks
11/17/201418:16:19Actavis To Buy Allergan In $66 Billion Deal--5th Update
11/17/201417:14:20MARKET SNAPSHOT: S&P 500 Registers 42nd Record Close In Skittish...
11/17/201416:28:40Actavis To Buy Allergan in $66 Billion Deal -- 5th Update
11/17/201416:06:13MARKET SNAPSHOT: S&P 500 Struggles Toward Record Close In Choppy...
11/17/201415:35:37Ackman, Valeant Can't Justify Topping Actavis Bid for Allergan
11/17/201411:28:48MARKET SNAPSHOT: U.S. Stocks Edge Lower; Baker Hughes Surges

Allergan and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad